Weak Provenge sales send Dendreon shares tumbling

Dendreon ($DNDN) had its biggest share price fall in 21 months last week after sales of prostate cancer vaccine Provenge fell short of expectations. The miss means Dendreon now expects to fail to achieve its modest goal of growing sales this year. Article

Suggested Articles

Merck has a big target in mind for its pneumococcal vaccine V114: Prevnar 13, the world's best-selling shot—and its phase 3 program shows it.

A Lancet Infectious Diseases study shows antibody response persists for two years or more after a single shot of Merck’s rVSV-ZEBOV vaccine.

Behind the under-pressure blockbuster Prevnar 13 are several pipeline vaccines Pfizer hopes will propel future growth.